|Józef Hałasa, Maciej Hałasa, Wiesława Wojciechowska, Izabela Podkowińska, Elżbieta Kucharska|
A total of 24 patients with nonatopic infectious asthma and COPD, demonstrating symptoms of infection-induced exacerbations were treated with autovaccine in the double blind, placebo controlled trial.
Autovaccine was prepared from autologic bacterial strains repeatedly isolated from the lower airways. Together with the strains commonly recognized as pathogenic in the airways (Haemophilus influenzae or Streptococcus pneumoniae), we also included those of so called physiologic strains (Streptococcus viridans or Neisseria species), which provoked early (after 15 min.), delayed (after 8-10 h) or late (after 24-48 h) skin test reactions in studied patients.
Analysis of the therapeutical effect in regard of both subjective and objective clinical parameters suggests high efficiency of autovaccine in treatment of nonatopic asthma and COPD.
In conclusion, the effect of treatment strongly depends on the quality of the autovaccine used. It has to include not only bacterial strains commonly recognized as pathogenic, but also those so called "physiologic" which induce allergic reactions in a number of patients.
Alergia Astma Immunologia, 2001, 6(2), 109-113
keywords: astma, POCH, bakterie, autoszczepionka, asthma, COPD, bacterial strains, autovaccine
pages: from 109 to 113
|estimated time of download (90 kB)|